Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Enterprise Value (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Enterprise Value for 4 consecutive years, with -$5.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Enterprise Value rose 91.45% year-over-year to -$5.7 million, compared with a TTM value of -$5.7 million through Sep 2025, up 91.45%, and an annual FY2024 reading of -$42.5 million, up 17.84% over the prior year.
  • Enterprise Value was -$5.7 million for Q3 2025 at Atara Biotherapeutics, up from -$22.3 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$5.7 million in Q3 2025 and bottomed at -$301.8 million in Q1 2022.
  • Average Enterprise Value over 4 years is -$78.5 million, with a median of -$48.9 million recorded in 2023.
  • The sharpest move saw Enterprise Value fell 3.47% in 2024, then soared 91.45% in 2025.
  • Year by year, Enterprise Value stood at -$93.1 million in 2022, then soared by 44.43% to -$51.7 million in 2023, then rose by 17.84% to -$42.5 million in 2024, then surged by 86.49% to -$5.7 million in 2025.
  • Business Quant data shows Enterprise Value for ATRA at -$5.7 million in Q3 2025, -$22.3 million in Q2 2025, and -$14.0 million in Q1 2025.